低风险孕妇早产筛查随机试验——早产筛查研究
该多中心非盲随机试验纳入1334例无既往早产史的无症状单胎孕妇,在18 0/7至23 6/7周随机分入经阴道超声宫颈长度筛查组或不筛查组。筛查组宫颈长度≤25 mm者予阴道黄体酮200 mg每日联合宫颈托。筛查组<37周早产率7.5%,对照组8.7%(RR 0.86,95%CI 0.59-1.25),差异无统计学意义。
要点
- 无症状单胎且无既往早产史孕妇中,孕中期普遍宫颈长度筛查未显著降低<37周早产率。
- 筛查组<37周早产7.5%(48例),对照组8.7%(54例),RR 0.86(95%CI 0.59-1.25)。
- 筛查组675例中13例(1.9%)宫颈长度≤25 mm,予阴道黄体酮200 mg每日联合宫颈托。
核心结论
- 在无既往自发性早产的單胎妊娠中,于18 0/6至23 6/7周引入普遍经阴道超声宫颈长度筛查并对宫颈长度≤25 mm者治疗,未导致早产发生率较不筛查显著降低。
研究设计与样本
- 多中心非盲随机试验,纳入无既往自发性早产的无症状单胎妊娠,随机分为宫颈长度筛查组(干预组)或不筛查组(对照组)。
- 受试者在孕18 0/7至23 6/7周常规解剖扫描时随机分组,筛查组接受宫颈长度测量。
- 共纳入1334例无症状单胎妊娠且无既往早产孕妇;筛查组675例。
- 主要结局为<37周早产,按意向筛查原则以相对危险度及95%置信区间量化。
主要发现
- 筛查组675例中13例(1.9%)经阴道超声宫颈长度≤25 mm。
- 筛查组<37周早产48例(7.5%),对照组54例(8.7%),相对危险度0.86(95%置信区间0.59-1.25)。
- 筛查组与对照组在<34、<32、<30、<28及<24周早产发生率上无显著差异。
关键数值与推荐
- 筛查组宫颈长度≤25 mm者予阴道黄体酮200 mg每日联合宫颈托。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Preterm birth is a major cause of perinatal morbidity and mortality. It is unclear whether the introduction of a universal transvaginal ultrasound cervical length screening program in women at low risk for preterm delivery is associated with a reduction in the frequency of preterm birth. OBJECTIVE: To test the hypothesis that the introduction of a midtrimester universal transvaginal ultrasound cervical length screening program in asymptomatic singleton pregnancies without prior preterm delivery would reduce the rate of preterm birth at <37 weeks of gestation. STUDY DESIGN: This study was a multicenter nonblinded randomized trial of screening of asymptomatic singleton pregnancies without prior spontaneous preterm birth, who were randomized to either cervical length screening program (ie, intervention group) or no screening (ie, control group). Participants were randomized at the time of their routine anatomy scan between 18 0/7 and 23 6/7 weeks of gestation. Women randomized in the screening group received cervical length measurement. Those who were found to have cervical length ≤25 mm were offered 200 mg vaginal progesterone daily along with cervical pessary. The primary outcome was preterm birth at <37 weeks. The risk of primary outcome was quantified by the relative risk with 95% confidence interval, and was based on the intention-to-screen principle. RESULTS: A total of 1334 asymptomatic women with singleton pregnancies and without prior preterm birth, were included in the trial. Out of the 675 women randomized in the transvaginal ultrasound cervical length screening group, 13 (1.9%) were found to have transvaginal ultrasound cervical length ≤25 mm during the screening. Preterm birth at <37 weeks of gestation occurred in 48 women in the transvaginal ultrasound cervical length screening group (7.5%), and 54 women in the control group (8.7%) (relative risk, 0.86; 95% confidence interval, 0.59-1.25). Women randomized in the transvaginal ultrasound cervical length screening group had no significant differences in the incidence of preterm birth at less than 34, 32, 30, 28, and 24 weeks of gestation. CONCLUSION: The introduction of a universal transvaginal ultrasound cervical length screening program at 18 0/6 to 23 6/7 weeks of gestation in singleton pregnancies without prior spontaneous preterm birth, with treatment for those with cervical length ≤25 mm, did not result in significant lower incidence of preterm delivery than the incidence without the screening program.
引用
- Saccone G, Maruotti GM, Morlando M, et al. Randomized trial of screening for preterm birth in low-risk women - the preterm birth screening study. Am J Obstet Gynecol MFM. 2024. PMID: 38642994. doi:10.1016/j.ajogmf.2023.101267
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。